NICE approves adalimumab for psoriasis

NICE has published guidance on the use of adalimumab (Humira), an anti-TNF agent for the treatment of psoriasis.

It recommends adalimumab as a treatment option for adults with plaque psoriasis for whom anti-TNF treatment is being considered and when both of the following criteria are fulfilled:

  • The disease is severe (defined as a Psoriasis Area Sensitivity Index [PASI] and a Dermatology Life Quality Index [DLQI] of more than 10).
  • The disease has not responded to previous therapies including ciclosporin, methotrexate and PUVA, or the patient is intolerant or has a contraindication to these treatments.
  • Adalimumab should be discontinued in patients whose psoriasis has not responded adequately at 16 weeks.

Read the full NICE guidance

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS bulletins

News and updates straight to your inbox.

Prescribing Update: Fortnightly news bulletin
Urgent prescribing updates
Spotlight: Disease-themed monthly round-up

Sign me up

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases